China's Wuxi Biologics Acquires Pfizer's Local Factory in China, "Expecting to Meet Pharmaceutical Manufacturing Demand"

[Image source=Reuters Yonhap News]

[Asia Economy Reporter Hyunwoo Lee] It has been reported that Chinese pharmaceutical company Wuxi Biologics is set to purchase a biosimilar production plant in China from Pfizer's China subsidiary. Although it has not been disclosed what medicines will be produced at the acquired facility, the plant is known to be equipped with cell culture facilities and capable of vial and syringe filling, suggesting that the purchase was made to meet the demand for vaccines and pharmaceuticals.

According to major foreign media on the 17th, Chinese pharmaceutical company Wuxi Biologics announced plans to acquire a biosimilar production plant in eastern Hangzhou owned by Pfizer's China subsidiary. Wuxi Biologics did not disclose the acquisition price or the medicines to be manufactured at the facility.

Wuxi Biologics has not revealed whether production related to COVID-19 vaccines will take place at the facility, but given the nature of the plant, it is expected that vaccine-related production will occur. Wuxi Biologics is currently known to produce the active ingredient of AstraZeneca's COVID-19 vaccine and supply it to Brazil.

Wuxi Biologics stated, "This acquisition contract is expected to be finalized within the first half of this year and will help address the rapidly increasing manufacturing demand for pharmaceuticals." They added, "The facility is equipped with bioreactors and has the capability for vial and syringe filling."

This content was produced with the assistance of AI translation services.